A decade-long class action lawsuit against Pfizer over alleged off-label Neurontin marketing is finally wrapping up, with U.S. District Judge Patti Saris approving a $325 million settlement on Monday. Health insurers and government payers had sued the drug giant for illegally promoting the med--at the time approved only to treat adult epilepsy and post-herpetic neuralgia--to treat maladies including bipolar disorder and migraines. More